Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
N Engl J Med
    April 2024
  1. PASSARO A, Peters S
    Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
    N Engl J Med. 2024;390:1325-1327.
    >> Share

  2. WU YL, Dziadziuszko R, Ahn JS, Barlesi F, et al
    Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:1265-1276.
    >> Share

  3. IZZEDINE H, Bouderlique E, Besse B
    Selpercatinib and Pseudo-Decreases in Kidney Function.
    N Engl J Med. 2024;390:1241-1243.
    >> Share

    February 2024
  4. ZHOU C, Agrawal T, Girard N
    VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
    N Engl J Med. 2024;390:579-580.
    >> Share

  5. MOIK F, Riedl JM, Ay C
    VTE with Amivantamab plus Chemotherapy in NSCLC.
    N Engl J Med. 2024;390:578-579.
    >> Share

  6. PLANCHARD D, Janne PA, Kobayashi K
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2024;390:478-479.
    >> Share

  7. VAN WAALWIJK VAN DOORN-KHOSROV, Badrising SK, Burgers S
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
    N Engl J Med. 2024;390:478.
    >> Share

    January 2024
  8. HEYMACH JV, Harpole D, Reck M
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2024;390:287-288.
    >> Share

  9. HORITA N, Fujiwara Y
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:287.
    >> Share

  10. DRILON A, Camidge DR, Lin JJ, Kim SW, et al
    Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:118-131.
    >> Share

    November 2023
  11. ZHOU C, Tang KJ, Cho BC, Liu B, et al
    Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
    N Engl J Med. 2023;389:2039-2051.
    >> Share

  12. PLANCHARD D, Janne PA, Cheng Y, Yang JC, et al
    Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2023;389:1935-1948.
    >> Share

  13. MULLIGAN L
    Selective RET Kinase Inhibitors and Lung Cancer.
    N Engl J Med. 2023;389:1913-1916.
    >> Share

  14. MCCANNON JB, Shepard JO, Wong AK, Thomas MF, et al
    Case 35-2023: A 38-Year-Old Woman with Waxing and Waning Pulmonary Nodules.
    N Engl J Med. 2023;389:1902-1911.
    >> Share

  15. ZHOU C, Solomon B, Loong HH, Park K, et al
    First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
    N Engl J Med. 2023;389:1839-1850.
    >> Share

  16. WU YL, Zhou Q
    Combination Therapy for EGFR-Mutated Lung Cancer.
    N Engl J Med. 2023 Nov 8. doi: 10.1056/NEJMe2311559.
    >> Share

    October 2023
  17. HEYMACH JV, Harpole D, Mitsudomi T, Taube JM, et al
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 23. doi: 10.1056/NEJMoa2304875.
    >> Share

  18. AHN MJ, Cho BC, Felip E, Korantzis I, et al
    Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 20. doi: 10.1056/NEJMoa2307980.
    >> Share

  19. PROVENCIO M, Massuti B, Romero A
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2023;389:1534-1535.
    >> Share

  20. VERMA S, Vincent M, Breadner D
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;389:1534.
    >> Share

  21. TSUBOI M, Herbst RS, Wu YL
    Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2023;389:1342.
    >> Share

  22. DI MAIO M
    Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med. 2023;389:1341-1342.
    >> Share

    August 2023
  23. SACHER A, LoRusso P, Patel MR, Miller WH Jr, et al
    Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
    N Engl J Med. 2023;389:710-721.
    >> Share

  24. LOVLY CM
    Perioperative Immunotherapy - A KEY toward Improved Outcomes for Early-Stage Lung Cancer?
    N Engl J Med. 2023;389:560-561.
    >> Share

    June 2023
  25. PROVENCIO M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, et al
    Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Jun 28. doi: 10.1056/NEJMoa2215530.
    >> Share

  26. TSUBOI M, Herbst RS, John T, Kato T, et al
    Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304594.
    >> Share

  27. WAKELEE H, Liberman M, Kato T, Tsuboi M, et al
    Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Jun 3. doi: 10.1056/NEJMoa2302983.
    >> Share

  28. BALDESSARI EM, Mesquida SM
    Phantom Tumor of the Lung.
    N Engl J Med. 2023;388:2086.
    >> Share

    April 2023
  29. ALTORKI N, Wang X, Stinchcombe TE
    Extent of Surgery for Stage IA Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2023;388:1629-1630.
    >> Share

  30. LI WWL, van der Heide SM, Verhagen AFTM
    Extent of Surgery for Stage IA Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;388:1629.
    >> Share

    February 2023
  31. RUSCH VW
    Initiating the Era of "Precision" Lung Cancer Surgery.
    N Engl J Med. 2023;388:557-558.
    >> Share

  32. ALTORKI N, Wang X, Kozono D, Watt C, et al
    Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;388:489-498.
    >> Share

    December 2022
  33. STRICKLER JH, Satake H, George TJ, Yaeger R, et al
    Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
    N Engl J Med. 2022 Dec 21. doi: 10.1056/NEJMoa2208470.
    >> Share

  34. ROBERTS MB, Lee J, Murphy MC, Kim AY, et al
    Case 37-2022: A 55-Year-Old Man with Fatigue, Weight Loss, and Pulmonary Nodules.
    N Engl J Med. 2022;387:2172-2183.
    >> Share

    November 2022
  35. TEMEL JS, Dudzinski DM, Digumarthy SR, Keyes CM, et al
    Case 35-2022: A 60-Year-Old Man with Progressive Dyspnea, Neck Swelling, and a Lung Mass.
    N Engl J Med. 2022;387:1889-1896.
    >> Share

    September 2022
  36. JANNE PA, Sabari JK, Spira AI
    Adagrasib in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2022;387:1238-1239.
    >> Share

  37. KOTECHA R, Sahgal A, Mehta MP
    Adagrasib in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2022;387:1238-1239.
    >> Share

    August 2022
  38. FORDE PM, Spicer J, Girard N
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.
    N Engl J Med. 2022;387:572-573.
    >> Share

  39. CAO C
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2022;387:571-572.
    >> Share

  40. TANVETYANON T
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2022;387:571.
    >> Share

    July 2022
  41. BOYCE M, Flower C
    Tripe Palms.
    N Engl J Med. 2022;387:355.
    >> Share

  42. RESTREPO D, Haramati A, McCluskey SM, Branda JA, et al
    Case 22-2022: A 34-Year-Old Woman with Cavitary Lung Lesions.
    N Engl J Med. 2022;387:261-269.
    >> Share

  43. PASSARO A, Peters S
    Setting the Benchmark for KRAS(G12C) -Mutated NSCLC.
    N Engl J Med. 2022;387:180-183.
    >> Share

    June 2022
  44. JANNE PA, Riely GJ, Gadgeel SM, Heist RS, et al
    Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation.
    N Engl J Med. 2022 Jun 3. doi: 10.1056/NEJMoa2204619.
    >> Share

    May 2022
  45. LI BT, Smit EF, Janne PA
    Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2022;386:1770-1771.
    >> Share

  46. TJONG MC, Mak RH, Louie AV
    Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2022;386:1770.
    >> Share

  47. VIRAY H, Rangachari D, Costa DB
    Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2022;386:1769-1770.
    >> Share

    April 2022
  48. FORDE PM, Spicer J, Lu S, Provencio M, et al
    Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    N Engl J Med. 2022 Apr 11. doi: 10.1056/NEJMoa2202170.
    >> Share

  49. LOVLY CM
    Expanding Horizons for Treatment of Early-Stage Lung Cancer.
    N Engl J Med. 2022 Apr 11. doi: 10.1056/NEJMe2203330.
    >> Share

    February 2022
  50. WING JR, Kimball A, Rengarajan M
    Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.
    N Engl J Med. 2022;386:781-787.
    >> Share

    January 2022
  51. PASSARO A, Peters S
    Targeting HER2-Mutant NSCLC - The Light Is On.
    N Engl J Med. 2022;386:286-289.
    >> Share

  52. HORN DM, Haas JS
    Expanded Lung and Colorectal Cancer Screening - Ensuring Equity and Safety under New Guidelines.
    N Engl J Med. 2022 Jan 8. doi: 10.1056/NEJMp2113332.
    >> Share

    September 2021
  53. JANES SM, Alrifai D, Fennell DA
    Perspectives on the Treatment of Malignant Pleural Mesothelioma.
    N Engl J Med. 2021;385:1207-1218.
    >> Share

  54. LI BT, Smit EF, Goto Y, Nakagawa K, et al
    Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2021 Sep 18. doi: 10.1056/NEJMoa2112431.
    >> Share

    June 2021
  55. AWAD MM, Liu S, Rybkin II, Arbour KC, et al
    Acquired Resistance to KRAS(G12C) Inhibition in Cancer.
    N Engl J Med. 2021;384:2382-2393.
    >> Share

  56. SKOULIDIS F, Li BT, Dy GK, Price TJ, et al
    Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
    N Engl J Med. 2021;384:2371-2381.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016